- Trial phase
- Approved
- Time to market
- Already approved and commercially launched (FDA approval December 2023)
- Why 4/10
- CASGEVY is already FDA-approved and commercially launched with no pending regulatory decision (PDUFA) in the next ~12 months. The next catalysts are commercial execution (quarterly revenue updates) and pipeline progress, not hard binary events. As an approved drug driving a single-product company's thesis, it scores 4, the defining binary (FDA approval) has already passed.
Watch quarterly CASGEVY revenue trends as the key value driver, Q3 2026 results (~Nov 2026) will show whether the 151% YoY growth rate is sustainable. The 19.4% short interest and 15.6 days to cover create squeeze potential on positive commercial surprises, but the lack of a near-term binary catalyst limits near-term trading conviction. The analyst mean target of $87.56 implies ~48% upside from current levels.
Price Chart
Executive Summary
CASGEVY (exagamglogene autotemcel) is the first FDA-approved CRISPR/Cas9 gene-edited therapy, developed by CRISPR Therapeutics (CRSP, Nasdaq) in partnership with Vertex Pharmaceuticals. Approved in December 2023 for sickle cell disease and beta-thalassemia, and expanded in 2026 to children aged 2+, it is a one-time cell therapy that edits a patient's own blood stem cells to boost fetal hemoglobin. Q2 2026 revenue reached $76M (+151% YoY), showing accelerating commercial adoption. CRSP trades at ~$59 with a mean analyst target of $87.56 (48% upside), but carries ~19.4% short interest. The stock's value is heavily concentrated in CASGEVY royalties, with the pipeline still early-stage.
How It Works
CASGEVY is a one-time gene-edited cell therapy. A patient's own blood stem cells are removed, edited using CRISPR/Cas9 technology to boost fetal hemoglobin production (which compensates for defective adult hemoglobin), and infused back into the patient. This addresses the root cause of sickle cell disease and beta-thalassemia.
Trial Status
FDA-approved in December 2023 for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). Expanded label in 2026 to include children aged 2 and older. CASGEVY is the first CRISPR-based gene-edited therapy approved by the FDA. It is being commercialized in partnership with Vertex Pharmaceuticals, which books 100% of global revenue and shares profits with CRISPR Therapeutics (CRSP receives ~40% of profits).
The Two-Sided Case
Upcoming Catalysts
- Continued commercial ramp and quarterly CASGEVY revenue updates (next: Q3 2026 earnings ~November 2026)
- Potential label expansions or real-world evidence readouts
- Pipeline progress on CTX131 (Phase 2 CAR-T) and in vivo/siRNA programs
Source Filing
The SecBot filing or press-release report that triggered this drug report:
CRISPR Therapeutics AG PRESS-RELEASE CRSP ·Originating report